Trial Profile
Effect of different pretherapeutic parameters on the therapeutic response measured by prostate-specific antigen 2 months after the radioligand therapy with 177Lu-PSMA-617
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 May 2017
Price :
$35
*
At a glance
- Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 25 May 2017 New trial record